October 2020
Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA’s newly loosened blood donation restrictions, and more.
Table of Contents
October 2020 Issue
A Day in the Life: Blood, Sweat, and Smears
In our newest series, hematologists working in a variety of settings provide a glimpse into their daily lives.
In this edition, Megan Nakashima, MD, peeks out...
Editor’s Corner: Move Over Millennials: Time to Teach Outside the Boundaries
The many meanings and purposes of the word “zoom” and its namesake technology are especially relevant in today’s educational environment. To prepare our educators,...
Reader Responses: Is 3 months of anticoagulation enough for a provoked VTE?
Here’s how readers responded to a You Make the Call question about the appropriate length of anticoagulation for a provoked DVT.
Disclaimer: ASH does not...
October 2020 Issue
Is Post-Discharge VTE Prophylaxis Necessary for Patients With COVID-19?
In hospitalized patients with COVID-19, the risk of venous thromboembolism (VTE) following discharge was not significantly greater compared with the VTE risk in patients...
Oliceridine Approved for Management of Acute Pain
Oliceridine, a parenterally administered μ-receptor opioid agonist, is approved for the management of moderate to severe acute pain in adults requiring an intravenous (IV)...
New “Buy American” Order Mandates Domestic Manufacturing of Essential Drugs
President Donald Trump signed a new executive order requiring that certain “essential” drugs and medical supplies purchased by the federal government be manufactured in...
FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin-blmf, an anti–B-cell maturation antigen (BCMA) antibody-drug conjugate therapy, received accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma...
Tafasitamab-cxix Receives Accelerated Approval for Relapsed/Refractory DLBCL
The FDA granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma...
Mavorixafor Mobilizes White Blood Cells in Patients With WHIM Syndrome
Long-term treatment with once-daily oral mavorixafor, an inhibitor of CXCR4, reduced the number of cutaneous warts and infections and effectively increased neutrophil and lymphocyte...
Short Telomere Length Increases Non-Relapse Mortality Risk After Allogeneic Transplant for MDS
According to research published in Blood, shorter telomere length was an independent risk factor for non-relapse mortality (NRM) and overall survival (OS) in patients...
Evaluating Post-Transplant Sorafenib Maintenance in FLT3-Mutated AML
For patients with acute myeloid leukemia (AML) and an FLT3-ITD mutation, maintenance treatment with the multitargeted tyrosine kinase inhibitor (TKI) sorafenib significantly prolonged relapse-free...
Diversity, Equity, and Inclusion in Hematology, and more
Diversity, Equity, and Inclusion in Hematology
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and...
IVIg and Rituximab-Based Regimens Are the Most Effective Treatments for CANOMAD Syndrome
Approximately one-third of patients with CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M paraprotein, cold agglutinins, and disialosyl antibodies) syndrome have a hematologic malignancy,...
Is Haploidentical Better Than Cord Blood Transplantation in Leukemia and Lymphoma?
Allogeneic hematopoietic cell transplantation with cord blood or haploidentical bone marrow extend access to transplantation for patients who lack a human leukocyte antigen (HLA)–matched...
NCI Partners with Cancer Research UK, JADPRO Appoints Beth Faiman as Editor-in-Chief, and more
Fred Hutchinson Researchers Receive $3.5-Million Grant for Inherited Blood Disorder Treatment
Hans-Peter Kiem, MD, PhD, and Roland Walter, MD, PhD, from the Fred Hutchinson Cancer...
Small Retrospective Study Suggests Thrombopoietin Receptor Agonists Are Safe, Likely Effective for ITP During...
Preliminary findings from an observational multicenter study suggest that temporary off-label use of thrombopoietin receptor agonists (TPO-RAs) for the treatment of severe and/or refractory...
Inhaled Vaporized Cannabis Yields No Analgesic Benefit in Patients With SCD
Inhalation of vaporized cannabis did not significantly reduce self-reported pain levels or disease-related symptoms in adults with sickle cell disease (SCD) compared with placebo,...
October 2020 Issue
Racism Persists in Medicine, Including Hematology
Medicine is not exempt from the explicit and implicit racism seen in other parts of American life.
When Deirdra Terrell, PhD, MPH, started attending...
Pulling Back the Curtain: Moshe Mittelman, MD
In this edition, Moshe Mittelman, MD, describes growing up in a newly established State of Israel, his military service, and how both experiences affected...
Rewriting the Rules of Blood Donation
What will the FDA’s newly loosened blood donation restrictions mean for donors, blood banks, and the safety of the national blood supply?
In the initial...
October 2020 Issue
You Make the Call: Is 3 months of anticoagulation enough for a provoked VTE?
This month, Keith McCrae, MD, discusses the appropriate length of anticoagulation for a provoked DVT.
And don't forget to check out next month's clinical dilemma...
How I Teach: Navigating the COVID Classroom
As the COVID-19 pandemic increased rapidly in the U.S. in March and April 2020, the Association of American Medical Colleges (AAMC) released guidance strongly...
